R&D News | pharmaphorum

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J ducks out of Bavarian Nordic vaccine partnerships

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis

News

Oxurion craters as failed trial cuts its pipeline down to on...

Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its drugs for diabetic eye disease had failed a phase 2 trial and will be terminated.

News

Nykode vaccine shows its worth in cervical cancer trial

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.

News

Curebase bags $40m to develop patient-centric trials platfor...

Curebase has raised $40 million in second-round financing that will help it run more complex interventional trials for its biopharma clients, according to chief executive Tom Lemberg.

News

AZ bites back at rivals with new Farxiga data in heart failu...

AstraZeneca's SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it back into contention with its main rival Jardiance from Boehringer Ingelheim and Eli L

News

Gilead dives deeper into NK cell therapies with Dragonfly de...

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cance

J&J ducks out of Bavarian Nordic vaccine partnerships

Oxurion craters as failed trial cuts its pipeline down to on...

Nykode vaccine shows its worth in cervical cancer trial

Curebase bags $40m to develop patient-centric trials platfor...

AZ bites back at rivals with new Farxiga data in heart failu...

Gilead dives deeper into NK cell therapies with Dragonfly de...

Five indications added to Pharmacy First prescribing scheme

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks